

PRODUCT INFORMATION



Tiplaxtinin

Item No. 9000450

CAS Registry No.: 393105-53-8
Formal Name: α -oxo-1-(phenylmethyl)-5-[4-(trifluoromethoxy)phenyl]-1H-indole-3-acetic acid

Synonyms: PAI-039, Tiplasinin

MF: C₂₄H₁₆F₃NO₄

FW: 439.4


Purity: \geq 98%

UV/Vis.: λ_{max} : 252, 328 nm

Supplied as: A crystalline solid

Storage: -20°C

Stability: \geq 4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Tiplaxtinin is supplied as a crystalline solid. A stock solution may be made by dissolving the tiplaxtinin in the solvent of choice, which should be purged with an inert gas. Tiplaxtinin is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF). The solubility of tiplaxtinin in these solvents is approximately 14, 25, and 33 mg/ml, respectively.

Tiplaxtinin is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, tiplaxtinin should first be dissolved in DMF and then diluted with the aqueous buffer of choice. Tiplaxtinin has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

Description

Tiplaxtinin is an inhibitor of plasminogen activator inhibitor 1 (PAI-1; IC₅₀ = 2.7 μ M for the human enzyme).¹ It inhibits differentiation of human adipocytes when used at a concentration of 5 μ M.² Tiplaxtinin (5 and 20 mg/kg) reduces tumor growth and microvessel density in a T24 bladder cancer mouse xenograft model.³ It prevents carotid artery occlusion, increases the time to occlusive thrombosis, and decreases the thrombus size in a rat model of ferric chloride-induced arterial thrombosis when administered at a dose of 1 mg/kg.⁴

References

1. Elokdah, H., Abou-Gharbia, M., Hennan, J.K., *et al.* Tiplaxtinin, a novel, orally efficacious inhibitor of plasminogen activator inhibitor-1: Design, synthesis, and preclinical characterization. *J. Med. Chem.* **47(14)**, 3491-3494 (2004).
2. Crandall, D.L., Quinet, E.M., El Ayachi, S., *et al.* Modulation of adipose tissue development by pharmacological inhibition of PAI-1. *Arterioscler. Thromb. Vasc. Biol.* **26(10)**, 2209-2215 (2006).
3. Gomes-Giacoaia, E., Miyake, M., Goodison, S., *et al.* Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. *Mol. Cancer Ther.* **12(12)**, 2697-2708 (2013).
4. Hennan, J.K., Morgan, G.A., Swillo, R.E., *et al.* Effect of tiplaxtinin (PAI-039), an orally bioavailable PAI-1 antagonist, in a rat model of thrombosis. *J. Thromb. Haemost.* **6(9)**, 1558-1564 (2008).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM